维生素K拮抗剂在心内科临床中的经典适应证
本文回顾维生素K拮抗剂与直接口服抗凝药的循证定位。多数房颤和静脉血栓栓塞症中直接口服抗凝药已成为首选,但在机械心脏瓣膜及中重度二尖瓣狭窄合并房颤等特定情形下,维生素K拮抗剂仍更受推荐。
要点
- 多数房颤与静脉血栓栓塞症中直接口服抗凝药已为首选。
- 机械心脏瓣膜伴或不伴房颤时,维生素K拮抗剂仍优于直接口服抗凝药。
- 中重度二尖瓣狭窄合并房颤时,维生素K拮抗剂仍是优选。
核心结论
- 直接口服抗凝药在多数房颤和静脉血栓栓塞症中已成为一线选择。
- 机械心脏瓣膜及中重度二尖瓣狭窄合并房颤等特定心脏适应证中,维生素K拮抗剂仍被优先选用。
研究设计与样本
- 本文为叙述性综述,梳理维生素K拮抗剂与直接口服抗凝药在不同心血管适应证中的循证定位。
主要发现
- 大型随机对照试验显示直接口服抗凝药在多数房颤和静脉血栓栓塞症中有效且安全。
- 在机械心脏瓣膜伴或不伴房颤患者中,直接口服抗凝药尚未被证实与维生素K拮抗剂同样有效或安全。
- 房颤合并中重度二尖瓣狭窄患者中,直接口服抗凝药亦未被证实与维生素K拮抗剂同样有效或安全。
关键数值与推荐
- 机械心脏瓣膜伴或不伴房颤:维生素K拮抗剂优先于直接口服抗凝药。
- 房颤合并中重度二尖瓣狭窄:维生素K拮抗剂优先于直接口服抗凝药。
临床怎么用
- 遇机械心脏瓣膜或中重度二尖瓣狭窄合并房颤患者,应优先考虑维生素K拮抗剂抗凝。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction Anticoagulation is a critical component in the treatment of cardiovascular diseases. Oral anticoagulant therapy began with the introduction of vitamin K antagonists (VKAs) in the 1950s, and since the 2010s, direct oral anticoagulants (DOACs) have become available. Large randomised controlled trials (RCTs) have demonstrated that DOACs are effective and safe compared with VKAs in most cases of atrial fibrillation (AF) and in venous thromboembolism (VTE). Consequently, DOACs are now the first choice in most such conditions. Beyond these primary indications, there are other indications where DOACs are effective and safe. 1 2 However, there remain specific cardiac indications and patient characteristics where VKAs are preferred. In cases such as mechanical heart valves (MHVs) with or without AF and AF with moderate-to-severe mitral stenosis, DOACs have not proven to be as effective or safe as VKAs. 3–5 Additionally, the effects...
引用
- Heart:Timeless therapeutics: cardiac indications for vitamin K antagonists in clinical practice
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。